Old Web
English
Sign In
Acemap
>
authorDetail
>
Rachel F. Gabitass
Rachel F. Gabitass
University of Surrey
Myeloid-derived Suppressor Cell
Medicine
Immunology
Cancer
Cytokine
4
Papers
521
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (4)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
The effects of gemcitabine and capecitabine combination chemotherapy and of low-dose adjuvant GM-CSF on the levels of myeloid-derived suppressor cells in patients with advanced pancreatic cancer
2014
Cancer Immunology, Immunotherapy
Nicola E. Annels
Victoria Shaw
Rachel F. Gabitass
Lucinda Billingham
Pippa Corrie
Martin Eatock
Juan W. Valle
David B. Smith
Jonathan Wadsley
David Cunningham
Hardev Pandha
John P. Neoptolemos
Gary Middleton
Show All
Source
Cite
Save
Citations (68)
Use of gemcitabine- (Gem) and fluropyrimidine (FP)-based chemotherapy to reduce myeloid-derived suppressor cells (MDSCs) in pancreatic (PC) and esophagogastric cancer (EGC).
2011
Journal of Clinical Oncology
Rachel F. Gabitass
Nicola E. Annels
J. Crawshaw
Hardev Pandha
Gary Middleton
Show All
Source
Cite
Save
Citations (12)
Elevated myeloid-derived suppressor cells in pancreatic, esophageal and gastric cancer are an independent prognostic factor and are associated with significant elevation of the Th2 cytokine interleukin-13
2011
Cancer Immunology, Immunotherapy
Rachel F. Gabitass
Nicola E. Annels
Deborah D. Stocken
Hardev A. Pandha
Gary Middleton
Show All
Source
Cite
Save
Citations (441)
Prevalence and prognostic significance of myeloid-derived suppressor cells and regulatory T cells in pancreatic and esophagogastric cancer
2010
Journal of Clinical Oncology
Rachel F. Gabitass
Nicola E. Annels
Hardev Pandha
Gary Middleton
Show All
Source
Cite
Save
Citations (0)
1